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SUMMARY
Background
Patients with irritable bowel syndrome with diarrhoea (IBS-D) experience
restriction in daily activities and decreased health-related quality of life (QOL).
Aim
To investigate effects of alosetron on patient-reported health-related QOL,
satisfaction and productivity in women with severe IBS-D.
Methods
A total of 705 women (severe IBS-D, Rome II criteria) randomised to
alosetron 0.5 mg QD, 1 mg QD, 1 mg BID, or placebo for 12 weeks were
studied. IBSQOL, treatment satisfaction, daily activities, and lost workplace
productivity (LWP) were evaluated at randomisation and Week 12.
Results
One or more doses of alosetron signiﬁcantly improved all IBSQOL domains
except for sexual function from baseline vs. placebo. The magnitude of
IBSQOL changes was consistent with a clinically meaningful effect. Alosetron
0.5 mg QD and 1 mg BID signiﬁcantly reduced IBS interference with social/
leisure activities and LWP from baseline vs. placebo [social/leisure (mean ±
S.E.) days lost:  6.7 ± 0.8,  7.0 ± 0.9, P < 0.01; LWP (mean ± S.E.) h lost:
 11.0 ± 3.3,  21.1 ± 4.1, P < 0.05 respectively]. Signiﬁcantly more patients
treated with alosetron reported satisfaction vs. placebo. Improvements in
IBSQOL, LWP, and treatment satisfaction signiﬁcantly correlated with global
improvement of IBS symptoms. The incidence of adverse events with alosetron
was low with constipation being the most commonly reported event. A single
case of ischaemic colitis occurred, in a patient receiving alosetron 0.5 mg QD.
Conclusions
In women with severe IBS-D, alosetron treatment, including 0.5 mg QD,
resulted in statistically signiﬁcant and clinically relevant improvements in
health-related QOL, restriction of daily activities and treatment satisfaction
over placebo. IBS symptom improvement corresponded with positive changes
in IBSQOL, LWP and treatment satisfaction.
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The impact of the irritable bowel syndrome (IBS)
reaches beyond abdominal pain and altered bowel habits.
Patients suffering with IBS, compared to individuals
without IBS, generally experience differing levels of
restriction in daily activities (e.g. diminished workplace
productivity and reduced physical/social functioning),
worse psychological well-being and lower quality of life.
The estimated total direct and indirect healthcare costs
associated with IBS are sixfold higher compared to
healthy individuals,
1, 2 and IBS patients are more likely
to undergo unnecessary abdominal surgeries than indi-
viduals without IBS.
3, 4 The burden of IBS on psychoso-
cial, economic, quality of life and daily function aspects
is even greater in patients with severe and refractory
symptoms.
5 The estimated proportion of IBS patients
considered to have severe symptoms ranges from 20% to
55%.
6
Although treatment includes dietary and lifestyle mod-
iﬁcations, patients with severe IBS with diarrhoea (IBS-D)
frequently require additional pharmacological therapy.
The choice of treatment is inﬂuenced by predominant
bowel habit, symptom severity and the impact of symp-
toms on quality of life. Disappointingly, the treatment
options for patients with severe IBS-D remain limited.
Alosetron is a selective 5-HT3 receptor antagonist that
has been shown to signiﬁcantly improve abnormal bowel
function and to relieve pain and discomfort in IBS-D.
7–18
Alosetron, at the 1 mg twice daily (BID) dose, improved
quality of life and workplace productivity in previous
randomised, controlled trials.
19–21 These effects were
associated with signiﬁcant overall treatment satisfac-
tion.
19 The current recommended starting dose of alose-
tron is 0.5 mg BID, which can be decreased to 0.5 mg
QD if signiﬁcant constipation occurs. Therefore, the
effect of the 0.5 mg QD dose of alosetron on patient-
reported health outcome measures warrants clinical eval-
uation.
Ischaemic colitis and complications of constipation
are known serious adverse events associated with alose-
tron; concern over these adverse events has led to the
use of the drug under a Risk Evaluation and Mitigation
Strategy (REMS) programme. Constipation is the most
common adverse event observed with alosetron treat-
ment, which occurs more frequently with increasing dos-
ages. The incidence of ischaemic colitis and
complications of constipation do not appear to be dose-
related.
22
The aim of the present study was to evaluate the
effect of alosetron on IBS-related quality of life,
restriction of daily activities (workplace productivity,
social/leisure activity, household activity), and treatment
satisfaction in women with severe IBS-D who had
inadequate responses to other IBS-D therapies in a
randomised, double-blind, placebo-controlled study that
included lower doses of alosetron than previously
reported.
MATERIALS AND METHODS
Patients were enrolled from June 2003 to June 2005 at
multiple study sites in the United States. Institutional
Review Boards at each individual site approved the
protocol. Patients provided written informed consent
upon study entry. The efﬁcacy data of alosetron on IBS
symptom relief from this study have been previously
reported.
15 Details of the clinical trial are publicly
accessible at clinicaltrials.gov, registration number:
NCT00067561.
Participants
Women aged 18 years or older, diagnosed with severe
IBS-D [at least 6 months of IBS-D symptoms as deﬁned
by the Rome II criteria
23] who had failed conventional
therapy were eligible for the study. In addition, patients
were required to report at least one of the following
symptoms to be eligible for the study:
(i) Severe IBS-D deﬁned as either diarrhoea occurring
 50% of the time with an average stool consistency
score  3.0, or an average stool consistency score  3.5.
The assessment of stool consistency was based on a 5-
point scale (1 = very hard, 2 = hard, 3 = formed,
4 = loose, 5 = watery).
(ii) In addition to meeting the diarrhoea and stool
consistency criteria, patients also needed to report at
least one of the following symptoms during the 2-week
screening period to be eligible for the study:
(a) Frequent and severe abdominal pain/discomfort
(average pain score  2.0; 5-point scale:
0 = none, 1 = mild, 2 = moderate, 3 = intense,
4 = severe); or
(b) Frequent bowel urgency or faecal incontinence
(urgency   50% of days); or
(c) Restriction of daily activities because of IBS
( 25% of the days).
Patients were required to discontinue use of IBS medi-
cation for 7 days prior to screening with the exception
of short-acting antidiarrheals (e.g. loperamide or
diphenoxylate), which could be taken  24 h prior to
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tion of mirtazapine were permitted.
Exclusion criteria
Exclusion criteria were the presence of a biochemical or
structural abnormality of the digestive tract (including is-
chaemic colitis, adhesions and impaired intestinal circu-
lation); concomitant unstable medical condition; or
history or evidence of bloody diarrhoea or abdominal
pain with rectal bleeding, chronic or severe constipation,
or complications from constipation. Patients who were
currently constipated or had no stool for three consecu-
tive days during the 2-week screening period were also
excluded.
Randomisation
Patients satisfying all inclusion and exclusion criteria
were randomly assigned (1:1:1:1) to placebo BID, alose-
tron 0.5 mg QD (plus placebo QD), alosetron 1 mg QD
(plus placebo QD), or alosetron 1 mg BID for 12 weeks.
Patients and all study site personnel were blinded to
treatment assignment. Patients were assigned to study
treatment in accordance with a central, blocked
randomisation schedule. Study drug compliance was
assessed for each patient using pill counts and recorded
via the telephone diary system.
All analyses were conducted using the intent-to-treat
(ITT) population which consisted of all subjects rando-
mised to treatment. The last observation carried forward
(LOCF) imputation method was used for missing values.
In the LOCF approach, missing responses were replaced
with the value of the last previous non-missing response.
Assessments
Quality of life data were collected via a disease-speciﬁc
questionnaire (IBSQOL) at Randomisation and Week 12,
using a recall period of the preceding 4 weeks. The
IBSQOL is designed to assess the impact of IBS on nine
dimensions of health status, including emotional func-
tioning, mental health, sleep behaviour, energy, physical
functioning, diet, social role, role physical and sexual
relations.
24 The IBSQOL has demonstrated validity and
reliability in prior prospective studies in IBS. Question-
naires to assess workplace productivity, restriction of
daily activities (i.e. household and social/leisure activities)
and treatment satisfaction were also administered at ran-
domisation and Week 12.
Lost workplace productivity (LWP), including time
lost from paid job(s) and reduced effectiveness at paid
job(s) due to IBS symptoms were assessed at baseline
and Week 12 by asking patients to recall the impact of
IBS symptoms during the preceding 4 weeks. LWP was
assessed only in subjects scheduled to work during the
study (approximately two thirds of the ITT population).
LWP was calculated as follows:
LWP ¼ A þ½ B  ð 1   CÞ 
where A = Hours missed from paid job(s) because of IBS
symptoms. B = Hours working at paid job(s) despite
experiencing interference of IBS symptoms. C = Per cent
effectiveness while working with symptoms at paid job(s).
Restriction of daily activities was evaluated through
measurement of interference of IBS symptoms with
social/leisure and household activities, which were also
assessed at randomisation and Week 12 by asking the
patient questions recalling the impact of IBS symptoms
during the preceding 4 weeks.
Treatment satisfaction
Patient treatment satisfaction was assessed at randomisa-
tion and Week 12 by the following question: ‘During the
past 4 weeks, how satisﬁed were you with the medica-
tion(s) you have used to treat your IBS symptoms?’ and
recorded a satisfaction score for their IBS medication
using a 7-point scale ranging from 1 = very satisﬁed to
7 = very unsatisﬁed.
Correlation with efﬁcacy on IBS symptom relief
Efﬁcacy results of alosetron on the IBS global improve-
ment scale (GIS) in this study have been previously pub-
lished.
15 We examined correlations between the changes
from baseline in quality of life domains, LWP, treatment
satisfaction and the GIS responses obtained.
Statistical analysis
All data analyses were performed using SAS (V8.2; copy-
right 1999–2001 SAS Institute, Cary, NC, USA). Changes
from baseline in scale-speciﬁc scores were computed for
all nine quality of life domains: energy, social function-
ing, mental health, physical role, physical functioning,
emotional, food/diet, sleep and sexual relations. For qual-
ity of life data, change from baseline to Week 12 in
transformed scale-speciﬁc scores were analysed using
analysis of covariance
25 with effects for treatment and
baseline transformed scale score as the covariate. Pair-
wise comparisons of each alosetron dose group versus
placebo were adjusted for the nine IBSQOL scales using
the general multiple Simes procedure described by Hom-
mel.
26
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days IBS symptoms interfered with social/leisure and
household activities were summarised and compared
between treatment groups using analysis of covariance
25
following rank transformation of the data with the base-
line value as a covariate.
Treatment satisfaction scores between groups were
compared at Week 12 (ITT-LOCF) using the Wilcoxon
rank sum test.
27 Also, for each treatment group, medica-
tion satisfaction with assigned treatment at Week 12 was
compared to the satisfaction of the previously used regi-
men at baseline using the sign-rank test.
28
Responder status and ratings for GIS at Week 12 were
correlated with IBSQOL, workplace productivity and
treatment satisfaction parameters using Spearman’s rank
correlation coefﬁcient.
28 Summary statistics (mean, s.d.)
of the changes in individual and aggregate quality of life
scales that were associated with positive changes in the
GIS were also obtained.
RESULTS
Demographics
Figure 1 describes the progression of patients in the
study. Full details of patients screened have been previ-
ously published.
15 Of the 705 women with severe IBS-D
who were randomised, at least 52% of patients in each
treatment group completed the study. The primary rea-
sons for premature discontinuation were adverse events
(86 patients, 12%) and withdrawal of consent (92
patients, 13%). Compliance with study treatment evalu-
ated from the telephone data entry system was similar
between groups, with 87–93% of patients reporting >80%
compliance.
There were no signiﬁcant differences in demographic
features, including IBS symptom severity between the
treatment arms at baseline (Table 1). All patients
reported restriction of daily activities from IBS symp-
toms on  25% of days with actual restrictions on 68–
70% of days.
Health-related quality of life changes
Statistically signiﬁcant improvements were observed for
at least one alosetron dose in all IBSQOL domains rela-
tive to placebo, with the exception of sexual relations
(Table 2).
Correlation of health-related quality of life changes
with IBS symptom improvement
Correlations between Week 12 global improvement of
IBS symptoms and changes from baseline in the nine
IBSQOL domains are reported in Table 3. For all nine
IBSQOL scales, improvements in change from baseline
scores were signiﬁcantly correlated with Week 12 global
improvement of IBS symptoms.
Productivity
Statistically signiﬁcant reductions in LWP were observed
in the 0.5 mg QD (decrease of 11.0 h; P < 0.05) and the
1 mg BID (decrease of 21.1 h; P < 0.001) groups com-
pared with placebo (decrease of 7.2 h) (Figure 2). The
change from baseline in LWP was negatively
Randomised (n = 705) 
Placebo group 
n = 176 
Discontinued 
n = 60 (34%) 
Adverse event (20) 
Consent withdrawn (16) 
Protocol violation (10) 
Lost to follow-up (3) 
Other (11) 
Discontinued 
n = 65 (37%) 
Adverse event (12) 
Consent withdrawn (19) 
Protocol violation (16) 
Lost to follow-up (7) 
Other (11) 
Completed 
n = 117 (66%) 
Completed 
n = 111 (63%) 
Alosetron 0.5 mg QD 
n = 177 
Discontinued 
n = 85 (48%) 
Adverse event (30) 
Consent withdrawn (33) 
Protocol violation (9) 
Lost to follow-up (2) 
Other (12) 
Completed 
n = 92 (52%) 
Alosetron 1.0 mg BID 
n = 177
Discontinued 
n = 74 (42%) 
Adverse event (24) 
Consent withdrawn (24) 
Protocol violation (15) 
Lost to follow-up (4) 
Other (13)
Completed 
n = 101 (58%) 
Alosetron 1.0 mg QD 
n = 175
Figure 1 | Patient disposition. QD, once daily; BID, twice daily.
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symptoms (Table 3), suggesting that reductions in LWP
were associated with improvements in global IBS
symptoms.
The number of days IBS symptoms caused restriction
of daily activities (interfered with social/leisure activities)
was signiﬁcantly reduced in the 0.5 mg QD and 1.0 mg
BID alosetron groups compared to placebo (P < 0.01)
(Figure 3a). Although the number of days IBS symptoms
interfered with household activities was reduced, the
treatment differences did not reach statistical signiﬁcance
compared with placebo (Figure 3b).
Treatment satisfaction
Signiﬁcant improvements in treatment satisfaction from
baseline to Week 12 were observed in all treatment groups
(P < 0.0001). At Week 12, signiﬁcantly higher proportions
of subjects in each alosetron dose group (P < 0.01)
reported better satisfaction with their IBS medication
compared with the placebo group (Figure 4). The number
of subjects expressing treatment satisfaction with placebo
increased from baseline by 29% to 45% after 12 weeks,
representing a treatment difference of 21% for alosetron
0.5 mg QD vs. placebo at Week 12 (Figure 4). Greater
satisfaction with IBS treatment at Week 12 was correlated
with the Week 12 global improvement of IBS symptoms
(Table 3).
Safety
Safety results for this study have been previously
reported.
15 In summary, incidences of adverse events
were similar across all treatment groups, with constipa-
tion being the most commonly observed adverse event.
Patients experiencing adverse events were included in
the analyses of patient-reported outcomes in this study.
The incidence of constipation was dose-related in the
alosetron groups (9%, 16%, and 19%, for the 0.5 mg
QD, 1 mg QD and 1 mg BID groups respectively). Three
serious adverse events were reported that were consid-
ered by investigators to be related to alosetron [two
patients on 0.5 mg QD (bowel obstruction, ischaemic
colitis]; one patient on 1 mg BID (faecal impaction)]. All
three adverse events resolved shortly after discontinua-
tion of treatment.
DISCUSSION
This randomised, placebo-controlled study demonstrated
that alosetron administration, including 0.5 mg QD, was
associated with improved measures of IBS-related quality
of life and treatment satisfaction in women with severe
IBS-D. Moreover, the 0.5 mg QD dose of alosetron was
associated with improvements in lost workplace
productivity, and resulted in fewer days of restriction of
daily activities caused by IBS symptoms. The effects of
alosetron on quality of life, workplace productivity and
Table 1 | Summary of demographic and baseline characteristics of study patients
Placebo
n = 176*
Alosetron
0.5 mg QD
n = 177*
Alosetron
1m gQ D
n = 175*
Alosetron
1 mg BID
n = 177*
Age (y) (Mean ± s.d.) 46.6 ± 14.5 45.9 ± 13.1 46.6 ± 12.3 47.0 ± 13.9
Ethnic origin [n (%)]
Caucasian 154 (88) 163 (92) 158 (90) 145 (87)
Black 10 (6) 8 (5) 5 (3) 10 (6)
Hispanic 10 (6) 6 (3) 10 (6) 12 (7)
Others 2 (1) (0) 2 (1) (0)
Quality of Life Scores (Mean ± S.E.)
Emotional 37.5 (1.8) 34.6 (1.7) 36.4 (1.9) 36.4 (1.7)
Mental health 57.8 (1.8) 58.3 (1.8) 58.9 (2.0) 58.7 (1.9)
Sleep 59.3 (1.8) 57.5 (1.8) 58.6 (1.8) 59.1 (1.8)
Energy 40.8 (2.0) 37.5 (2.0) 38.6 (2.0) 38.7 (1.8)
Physical functioning 56.3 (1.8) 55.9 (1.8) 57.6 (2.1) 55.5 (2.0)
Food/diet 48.7 (1.7) 44.9 (1.7) 46.0 (1.9) 46.9 (1.7)
Social functioning 32.0 (1.7) 31.5 (1.7) 32.1 (1.8) 32.3 (1.8)
Physical role 29.4 (1.8) 32.0 (1.8) 31.3 (1.8) 30.2 (1.8)
Sexual relations 53.9 (2.8) 51.8 (2.4) 52.7 (2.6) 55.9 (2.5)
Lost workplace productivity (h) (Mean ± S.E.) 31.2 (3.0) 33.5 (3.0) 32.2 (3.2) 34.6 (4.2)
BID, twice daily; ITT, intent-to-treat; QD, once daily.
* ITT population (N = 705).
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Randomised clinical trial: alosetron improves outcomes in severe IBS-DTable 2 | IBSQOL scores [mean (S.E.)] for the alosetron treatment groups and placebo at baseline and Week 12
Domain
Placebo
n = 176*
Alosetron 0.5 mg QD
n = 177*
Alosetron 1 mg QD
n = 175*
Alosetron 1 mg BID
n = 177*
Emotional
n† 170 170 169 166
Baseline 37.5 (1.8) 34.6 (1.7) 36.4 (1.9) 36.4 (1.7)
Change from baseline 16.3 (1.9) 26.5 (1.9) 21.4 (1.9) 23.4 (2.0)
Treatment difference – 10.1 (2.7) 5.1 (2.7) 7.1 (2.8)
P-value‡– 0.001 0.066 0.021
Mental health
n† 170 171 169 166
Baseline 57.8 (1.8) 58.3 (1.8) 58.9 (2.0) 58.7 (1.9)
Change from baseline 10.2 (1.6) 19.7 (1.6) 14.9 (1.6) 17.3 (1.6)
Treatment difference – 9.5 (2.2) 4.7 (2.2) 7.0 (2.2)
P-value‡– <0.001 0.036 0.003
Sleep
n† 176 177 174 171
Baseline 59.3 (1.8) 57.5 (1.8) 58.6 (1.8) 59.1 (1.8)
Change from baseline 13.4 (1.5) 18.4 (1.5) 16.6 (1.5) 18.7 (1.5)
Treatment difference – 5.0 (2.1) 3.2 (2.1) 5.3 (2.2)
P-value‡– 0.038 0.141 0.029
Energy
n† 176 177 174 171
Baseline 40.8 (2.08) 37.5 (2.0) 38.6 (2.0) 38.7 (1.8)
Change from baseline 17.4 (2.0) 31.6 (2.0) 25.8 (2.0) 28.1 (2.1)
Treatment difference – 14.2 (2.9) 8.4 (2.9) 10.7 (2.9)
P-value‡– <0.001 0.004 <0.001
Physical functioning
n† 175 171 170 165
Baseline 56.3 (1.8) 55.9 (1.8) 57.6 (2.1) 55.5 (2.0)
Change from baseline 15.7 (1.6) 21.9 (1.7) 19.6 (1.7) 20.1 (1.7)
Treatment difference – 6.2 (2.3) 3.9 (2.3) 4.4 (2.4)
P-value‡– 0.024 0.094 0.094
Food/diet
n† 176 177 174 170
Baseline 48.7 (1.7) 44.9 (1.7) 46.0 (1.9) 46.9 (1.7)
Change from baseline 13.7 (1.7) 22.8 (1.7) 19.1 (1.7) 19.8 (1.7)
Treatment difference – 9.1 (2.4) 5.4 (2.4) 6.1 (2.4)
P-value‡– <0.001 0.023 0.02
Social functioning
n† 175 177 174 171
Baseline 32.0 (1.7) 31.5 (1.7) 32.1 (1.8) 32.3 (1.8)
Change from baseline 16.9 (1.9) 27.0 (1.9) 22.9 (2.0) 26.5 (2.0)
Treatment difference – 10.0 (2.7) 6.0 (2.8) 9.6 (2.8)
P-value‡– 0.001 0.031 0.001
Physical role
n† 175 177 173 171
Baseline 29.4 (1.8) 32.0 (1.8) 31.3 (1.8) 30.2 (1.8)
Change from baseline 17.3 (2.1) 28.5 (2.1) 23.5 (2.1) 24.7 (2.1)
Treatment difference – 11.2 (2.9) 6.2 (3.0) 7.5 (3.0)
P-value‡– <0.001 0.036 0.024
Sexual relations
n† 89 104 97 103
Baseline 53.9 (2.8) 51.8 (2.4) 52.7 (2.6) 55.9 (2.5)
Change from baseline 11.4 (2.4) 16.6 (2.2) 18.0 (2.3) 18.7 (2.2)
Treatment difference – 5.3 (3.2) 6.7 (3.3) 7.3 (3.2)
P-value‡– 0.103 0.084 0.063
BID, twice daily; ITT, intent-to-treat; LOCF, last observation carried forward; QD, once daily.
* ITT population (n = 705); scores presented for baseline, change from baseline, and treatment difference are mean (S.E.).
† LOCF imputed from the ITT population.
‡ Change from baseline to Week 12 in transformed scale-speciﬁc scores were analysed using analysis of covariance with effects
for treatment and baseline transformed scale score as the covariate. P-values were adjusted for multiple comparisons using the
general multiple Simes procedure described by Hommel.
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with drug efﬁcacy, as reﬂected by improvement of global
IBS symptoms. Since there are limited clinical trial data
on the important association between symptom improve-
ment and health outcomes in IBS patients, it is
signiﬁcant when therapeutic responses to IBS treatments
are reported to correspond with positive changes in
health-related quality of life measures.
29
The clinical importance of the adverse impact of IBS on
patients’ ability to function normally, and on their sense
of well-being, is increasingly recognised by healthcare pro-
fessionals. The negative consequences of IBS on quality of
life, productivity and daily activities worsen with disease
severity, intensity, duration and frequency of doctor vis-
its
30 as patients run out of effective treatment options for
their severe abdominal and bowel symptoms.
Alosetron is the only prescription medication
approved by the FDA for treatment of severe IBS-D in
women who have failed conventional treatment. The
dosing regimen for alosetron can be adjusted depending
on patient response from an initial starting dose of
0.5 mg BID to a maximum of 1 mg BID.
In the present study, the improvement in quality of
life, compared to placebo, was present in eight of nine
domains and generally appeared more marked at the
lowest dose of alosetron. Sexual dysfunction did not
improve for reasons that are not clear; however, it is of
note that the sample population was lower than in the
other eight domains, possibly because patients were
uncomfortable answering questions regarding sexual
activity. However, improvement in sexual dysfunction
trended towards statistical signiﬁcance with alosetron
1m gQ D( P = 0.084) and 1 mg BID (P = 0.063) doses
(Table 2). The observed differences between active treat-
ment groups and placebo in scores for individual quality
of life domains ranged between 11% and 75% approxi-
mately (percentage treatment difference: active group
change from baseline – placebo change from baseline/
change from baseline for active group*100). Changes
from baseline scores of 18 points in a similar quality of
life instrument were previously found to be statistically
signiﬁcant and clinically relevant in a controlled trial of
cognitive-behavioural treatment in IBS,
31 and a mini-
mum change of 14 in quality of life scores was found to
be clinically meaningful in association with pharmaco-
logical or psychological treatments for IBS patients.
32
The magnitude of improvements observed with alosetron
in this study was larger than that determined to be rele-
vant previously (however, the improvement of IBSQOL
in the placebo group should also be recognised). This
BL Week 12 BL Week 12 BL Week 12 BL Week 12
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PBO
n = 116†
Alosetron
0.5 mg QD
n = 116†
Alosetron
1 mg QD
n = 125†
Alosetron
1 mg BID
n = 114†
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–21.1 h *
***
M
e
a
n
 
(
S
.
E
.
)
 
l
o
s
t
 
w
o
r
k
p
l
a
c
e
 
p
r
o
d
u
c
t
i
v
i
t
y
 
(
h
)
†LOCF imputed from the ITT population at Week 12. Lost workplace productivity was
assessed over the preceding 4 weeks at baseline and Week 12. LWP was summarized
and compared between treatment groups using analysis of covariance following rank
transformation of the data with the baseline value as a covariate.
Figure 2 | Mean number of hours of lost workplace productivity at baseline and Week 12 for the placebo (PBO) and
alosetron treatment groups. BL, baseline; QD, once daily; BID, twice daily. *P < 0.05, ***P < 0.001, signiﬁcantly
different from placebo.
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Randomised clinical trial: alosetron improves outcomes in severe IBS-Dsuggests that the effects of alosetron on quality of life
reported in this study are robust and clinically meaning-
ful.
A positive effect of alosetron on overall productivity
was also observed, with the highest dose of alosetron
being associated with the largest number of work hours
gained and the least interference with normal daily activ-
ities. Improvements observed with the alosetron 0.5 mg
QD dose resulted in approximately 50% more hours of
work gained (approximately 4 h gained), and 45% fewer
days of IBS symptom interference compared with pla-
cebo. This compared to an earlier prospective, natural
history study, in which IBS patients lost approximately
35% productivity per 40-h workweek,
33 and of a survey
of 1776 employees in a US banking institution, where
IBS patients lost an average of 15% of work hours.
34 The
effects of alosetron appear relevant, even at 0.5 mg QD,
which generally produced comparable effects to the
1 mg BID dose in this study.
In this study the intermediate (1 mg QD) dose of alose-
tron did not have signiﬁcant effects on physical function-
ing, emotional, sleep, or sexual relations quality of life
domains, workplace productivity, or restriction of daily
activities. This may indicate that side effects at the 1 mg
QD dose may detract from perceived treatment beneﬁt,
whereas at the largest 1 mg BID dose the magnitude of
physiological improvement on pain and bowel function
may overshadow the impact of side effects, resulting in
greater overall improvement in quality of life, workplace
productivity, restriction of daily activities and treatment
satisfaction. However, these conclusions are speculative as
the determinants of quality of life, productivity, lifestyle
activities and medication satisfaction remain innumerable.
The effects of alosetron 1 mg BID on quality of life
and workplace productivity reported in this study are
consistent with previous data.
19–21 However, the magni-
tude of improvements elicited by alosetron was generally
greater in this study, possibly due to the larger treatment
response that may be expected in patients with severe
IBS-D. However, an alternative explanation may be
regression to the mean, as symptom and IBSQOL scores
were greater at baseline.
In this study, summary values of changes in the indi-
vidual domains of IBSQOL, lost workplace productivity,
daily activities and treatment satisfaction are reported;
these changes correspond to clinically relevant improve-
ments of IBS symptoms. The greatest positive changes in
moderate or substantial improvement of global symp-
toms after 12 weeks of treatment occurred in the energy
domain of the IBSQOL, however, a positive change was
reported in all evaluated components. The summary data
reported in this study may provide the basis for planning
and interpretation of future studies assessing the effect of
therapeutics on measures of quality of life, workplace
productivity, daily activities and treatment satisfaction in
IBS patients.
There are potential limitations to the interpretation of
the data presented in this study. First, the trial popula-
tion is entirely women, a gender imbalance that is char-
acteristic of IBS and its referral pattern; moreover,
alosetron is currently labelled exclusively for female use.
Clinical studies in men suggest similar effects on ade-
quate relief of pain and discomfort,
17 however, there are
currently no studies formally assessing the effect of
alosetron on quality of life, productivity and lifestyle in
male patient populations. Second, global improvement
endpoints used in alosetron studies have been criticised
as not being fully representative of the complexity of
IBS. Indeed, more recent FDA guidance on acceptable
IBS clinical trial endpoints recommends use of a primary
endpoint that speciﬁcally measures the effect of
treatment on two major IBS symptoms (i.e. abdominal
pain intensity and stool consistency for IBS-D).
35, 36
Nonetheless, global endpoints continue to show validity
Table 3 | Correlations between improvements in
changes from baseline in quality of life domains,
workplace productivity and treatment satisfaction vs.
Week 12 global improvement of IBS symptoms. Results
reported were all statistically signiﬁcant and
moderately correlated
Outcome measure
Spearman
coefﬁcient* P-value
Quality of life domain
Emotional 0.53 <0.0001
Mental health 0.44 <0.0001
Sleep 0.38 <0.0001
Energy 0.51 <0.0001
Physical functioning 0.40 <0.0001
Food/diet 0.51 <0.0001
Social functioning 0.57 <0.0001
Physical role 0.53 <0.0001
Sexual relations 0.45 <0.0001
Lost workplace productivity  0.34 <0.0001
Treatment satisfaction  0.56 <0.0001
GIS, global improvement scale; IBS, irritable bowel syndrome;
IBSQOL, irritable bowel syndrome quality of life.
* Responder status and ratings for GIS at Week 12 were corre-
lated with IBSQOL, workplace productivity and treatment satis-
faction parameters using Spearman’s rank correlation
coefﬁcient.
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37 and Krause and
colleagues previously reported the correlation of global
improvement in IBS symptoms with relief of pain,
discomfort, stool form and other gastrointestinal
symptoms,
15 supporting the adequacy and usefulness of
the GIS primary endpoint. Third, the authors observed
adverse events even at lower doses of alosetron.
Ischaemic colitis and complications of constipation are
the most severe adverse events reported with alosetron
use.
38, 39 Ischaemic colitis appears to have a higher
background incidence in patients with a diagnosis of IBS
than in the general population, irrespective of IBS medi-
cal treatment.
40 In this study, adverse events were self-
limiting and resolved without long-term sequelae. A
(a) Social/leisure activities 
0
†LOCF imputed from the ITT population at Week 12. Number of days IBS interfered with 
social/leisure activities (Figure 3a) or household activities (Figure 3b) over the preceding 
4 weeks at baseline and Week 12. Social/leisure or household activities were summarized 
and compared between treatment groups using analysis of covariance following rank 
transformation of the data with the baseline value as a covariate.
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Figure 3 | Mean number of days IBS symptoms interfered with (a) social/leisure and (b) household activities at
baseline and Week 12 for the placebo (PBO) and alosetron treatment groups. BL, baseline; QD, once daily; BID, twice
daily. **P < 0.01, signiﬁcantly different from placebo.
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Randomised clinical trial: alosetron improves outcomes in severe IBS-Drecent review
22 summarised the clinical outcomes of is-
chaemic colitis and complications of constipation in
patients with severe IBS-D under alosetron treatment.
The cases were reviewed in the framework of a risk
management plan, established since the reintroduction of
alosetron to the US market in 2002. All cases reported in
patients with severe IBS-D resolved or improved upon
withdrawal of alosetron without serious sequelae.
22
Not all adverse events of alosetron are correlated to drug
dose. Although constipation appears to be dose-dependent,
ischaemic colitis and complications of constipation do not
seem to be. In this large study, a single case of reversible is-
chaemic colitis was observed at the lower 0.5 mg QD dose
of alosetron.
In this study, we observed a substantial number of
dropouts across all treatment groups. Although this
could suggest a relationship with poor treatment tolera-
bility in the highest dose group, a 37% dropout
rate was observed in the placebo group, suggesting that
a disorder such as severe IBS-D itself would, at least in
part, explain such high rates of discontinuation.
The potential bias of the LOCF imputation method
was assessed by comparison to the analysis of GIS
responders using observed data with no imputation,
and analysis of the data imputed as missing equals
non-responder. These comparisons were similar to the
LOCF imputation method, except for the Week 12
missing equals non-responder comparison between
alosetron 1 mg BID and placebo (data not shown).
These results indicate minimal bias in the LOCF impu-
tation method towards the treatment difference in the
proportion of GIS responders at Weeks 4 and 8; how-
ever, at Week 12 some impact was apparent due to the
greater amount of missing data for the alosetron 1 mg
BID group. Importantly, it should be noted that
changes in quality of life domains, workplace productiv-
ity and treatment satisfaction at Week 12 were moder-
ately correlated to GIS based on the ITT-LOCF
analyses, thereby suggesting minimal bias across these
study end points.
The evidence that ischaemic colitis is reversible in the
setting of alosetron administration is reassuring. More-
over, the data presented in this study are a reminder of
the likely idiopathic mechanisms underlying the develop-
ment of ischaemic colitis. This point is further supported
by the rare and stable incidence rates of ischaemic colitis
associated with alosetron treatment since the initial mar-
keting period to post reintroduction.
22 Nonetheless, the
evidence of the positive effect of a lower dose of alose-
tron on bowel symptom relief and meaningful effects on
BL Week 12 BL Week 12 BL Week 12 BL Week 12
0
†LOCF imputed from the ITT population at Week 12. Treatment satisfaction scores
between groups were compared at Week 12 using the Wilcoxon rank sum test.
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Figure 4 | Proportion of patients satisﬁed with their IBS treatment at baseline and Week 12 for the placebo (PBO) and
alosetron treatment groups. BL, baseline; QD, once daily; BID, twice daily. **P < 0.01 signiﬁcantly different from
placebo, ***P < 0.0001 signiﬁcantly different from baseline.
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ﬂexibility in alosetron dosing.
In summary, this study demonstrates that treatment
with alosetron across multiple doses, including once
daily, leads to signiﬁcant improvements in quality of life,
work productivity, social/leisure activities and treatment
satisfaction in women with severe IBS-D. Moreover,
these changes were moderately and signiﬁcantly corre-
lated with improvements in global IBS symptoms.
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